TY - JOUR
T1 - Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach
T2 - Indonesian Perspective - An Expert Opinion
AU - Lydia, Aida
AU - Suastika, Ketut
AU - Martosuwignjo, Pranawa
AU - Sibarani, Roy Panusunan
AU - Nasution, Sally Aman
AU - Sulistijo, Soebagijo Adi
N1 - Publisher Copyright:
© 2022, Indonesian Society of Internal Medicine. All rights reserved.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Indonesia ranks seventh with the highest number of cases of type 2 diabetes mellitus (T2DM). T2DM is associated with major undesirable complications including cardiovascular disease and chronic kidney disease. Kidneys play a major role in maintaining glucose homeostasis, leading the development of sodium glucose transporter inhibitors (SGLT2i). These inhibitors block renal sodium and glucose reabsorption. Several cardiovascular trials proved that SGLT2i have cardioprotective and renoprotective roles and have been suggested as a drug of choice in primary and secondary prevention and management of cardiorenal complications associated with T2DM. This review highlights the need for a multidisciplinary recommendation for T2DM management in Indonesian population. Additionally, it is vital to provide the perspective of Indonesian medical experts in terms of screening, diagnosis and treatment as the outcome differs geographically. An expert panel of 6 members from Indonesia was convened to review the existing literature and develop an expert-based review/ summary on this topic. Members were chosen for their proficiency in diabetes, kidney disease and cardiovascular disease. The experts opined that the early use of SGLT2i will be effective in preventing and minimising the progression of cardiorenal complications. Moreover, a consistent multidimensional approach is necessary for improved outcomes.
AB - Indonesia ranks seventh with the highest number of cases of type 2 diabetes mellitus (T2DM). T2DM is associated with major undesirable complications including cardiovascular disease and chronic kidney disease. Kidneys play a major role in maintaining glucose homeostasis, leading the development of sodium glucose transporter inhibitors (SGLT2i). These inhibitors block renal sodium and glucose reabsorption. Several cardiovascular trials proved that SGLT2i have cardioprotective and renoprotective roles and have been suggested as a drug of choice in primary and secondary prevention and management of cardiorenal complications associated with T2DM. This review highlights the need for a multidisciplinary recommendation for T2DM management in Indonesian population. Additionally, it is vital to provide the perspective of Indonesian medical experts in terms of screening, diagnosis and treatment as the outcome differs geographically. An expert panel of 6 members from Indonesia was convened to review the existing literature and develop an expert-based review/ summary on this topic. Members were chosen for their proficiency in diabetes, kidney disease and cardiovascular disease. The experts opined that the early use of SGLT2i will be effective in preventing and minimising the progression of cardiorenal complications. Moreover, a consistent multidimensional approach is necessary for improved outcomes.
KW - Cardiorenal complications
KW - SGLT2i
KW - Type 2 Diabetes Mellitus
UR - http://www.scopus.com/inward/record.url?scp=85145957315&partnerID=8YFLogxK
M3 - Review article
C2 - 36624712
AN - SCOPUS:85145957315
SN - 0125-9326
VL - 54
SP - 653
EP - 663
JO - Acta medica Indonesiana
JF - Acta medica Indonesiana
IS - 4
ER -